Abnormally strong functional linkage between cortical areas has been postulated to play a role in the pathogenesis of partial epilepsy. We explore the possibility that such linkages may be manifest in the interictal EEG apart from epileptiform disturbances or visually evident focal abnormalities. We analyzed samples of interictal intracranial EEG (ICEEG) recorded from subdural grids in nine patients with medically intractable partial epilepsy, measuring interelectrode synchrony using the mean phase coherence algorithm. This analysis revealed areas of elevated local synchrony, or "hypersynchrony" which had persistent spatiotemporal characteristics that were unique to each patient. Measuring local synchrony in a subdural grid results in a map of the cortical surface that provides information not visually apparent on either EEG or structural imaging. We explore the relationship of hypersynchronous areas to the clinical evidence of seizure localization in each case, and speculate that local hypersynchrony may be a marker of epileptogenic cortex, and may prove to be a valuable aid to clinical ICEEG interpretation.

Key Points• Del(18p), together with del(17p)/TP53 mutations, is present at a high frequency before ibrutinib treatment.• BTK mutations drive ibrutinib relapse, but del(17p)/TP53 mutations may be dispensable.Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment options. Mutations in BTK and PLCG2 have emerged as main mechanisms of drug resistance, but not all patients carry these mutations. Further understanding of mechanisms of resistance is urgently needed and will support rational development of new therapeutic strategies. To that end, we characterized the genomic profiles of serial samples from 9 patients with ibrutinib-relapsed disease, including 6 who had Richter transformation. Mutations, indels, copy-number aberrations, and loss of heterozygosity were assessed using next-generation sequencing and single-nucleotide polymorphism array. We found that 18p deletion (del(18p)), together with del(17p)/TP53 mutations, was present in 5 of 9 patients before ibrutinib therapy. In addition to BTK C481 , we identified BTK T316A, a structurally novel mutation located in the SH2 domain of BTK. Minor BTK clones with low allele frequencies were captured in addition to major BTK clones. Although TP53 loss predisposes patients for relapse, clone size of TP53 loss may diminish during disease progression while mutant BTK clone expands. In patients who had Richter transformation, we found that the transformed cells were clonal descendants of circulating leukemia cells but continued to undergo evolution and drifts.Surprisingly, transformed lymphoma cells in tissue may acquire a different BTK mutation from that in the CLL leukemia cells. Collectively, these results provide insights into clonal evolution underlying ibrutinib relapse and prompt further investigation on genomic abnormalities that have clinical application potential.

Background Risk factors for therapy-related leukemia (TRL) development, an often lethal late complication of cytotoxic therapy, remain poorly understood and may differ for survivors of different malignancies. Breast cancer (BC) survivors now account for the majority of TRL cases, making study of TRL risk factors in this population a priority. Methods Patients with TRL following cytotoxic therapy for a primary BC were identified from The University of Chicago TRL registry. Those with an available germline DNA sample were screened with a comprehensive gene panel covering known inherited BC susceptibility genes. Clinical and TRL characteristics of all subjects and those with identified germline mutations are described. Results Nineteen (22%) of 88 BC survivors with TRL had an additional primary cancer and 40 (57%) of the 70 with available family history had a close relative with breast, ovarian, or pancreatic cancer. Of the 47 subjects with available DNA, 10 (21%) were found to carry a deleterious inherited mutation in: BRCA1 (n=3, 6%), BRCA2 (n=2, 4%), TP53 (n=3, 6%), CHEK2 (n=1, 2%), and PALB2 (n=1, 2%). Conclusions BC survivors with TRL have personal and family histories suggestive of inherited cancer susceptibility and frequently carry germline mutations in BC susceptibility genes. These data support the role of these genes in TRL risk and suggest that long term follow-up studies of women with germline mutations treated for BC and functional studies of the effects of heterozygous mutations in these genes on bone marrow function following cytotoxic exposures are warranted.

collaborated on a comparison of cardiac output methods in which some of the data herein presented were used. 372

BackgroundNovel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well as in combination with anthracyclines and/or DNA-damaging agents.MethodsWe report the findings of a phase I dose escalation trial with cohort expansion in 20 patients with newly diagnosed or relapsed/refractory AML that combined selinexor with age-adjusted high-dose cytarabine and mitoxantrone (HiDAC/Mito).ResultsThree (15%) patients received the initial dose of 60 mg of selinexor (~ 35 mg/m2), and 17 (85%) received the target level of 80 mg (~ 50 mg/m2). No dose-limiting toxicities were observed. Common adverse events included febrile neutropenia (70%), diarrhea (40%), anorexia (30%), electrolyte abnormalities (30%), bacteremia (25%), cardiac toxicities (25%), fatigue (25%), and nausea/vomiting (25%). None were unexpected given the HiDAC/Mito regimen. Serious adverse events occurred in 6 (30%) patients; one was fatal. Ten (50%) patients achieved a complete remission (CR), 3 (15%) achieved CR with incomplete recovery (CRi), 1 (5%) achieved partial remission (PR), and 6 (30%) had progressive disease for an overall response rate (ORR) of 70%. Eight of 14 (57%) responders proceeded to allogeneic stem cell transplantation. Correlative studies of WT1 levels showed persistently detectable levels in patients who either did not respond or relapsed quickly after induction.ConclusionThe selinexor/HiDAC/Mito regimen is feasible and tolerable at selinexor doses of 80 mg/day (~ 50 mg/m2/day) twice weekly. The recommended phase II dose is 80 mg and warrants further study in this combination.Trial registrationClinicalTrials.gov, NCT02573363. Registered October 5, 2015

No abstract

The present study was guided by the hypothesis that temporal lobe epilepsy psychosis is associated with a definable syndrome of deficits in the higher cortical functions. Comparison was made of the mental content and mechanisms observed during psychotic episodes, seizures, dreams, and responses to electrical brain stimulation occurring in diverse combinations in 5 patients with drug-refractory temporal lobe epilepsy referred for neurosurgical treatment. Neurological, neuroradiological, EEG, and neuropsychiatric base lines were available before onset of the psychosis. Psychiatric manifestations were related to the interaction of disturbances in specific higher cortical functions and individual dynamic configurations. Interpatient variation in psychotic symptomatology arose from significant elements in the patient's past and current emotional life which provided the psychosis with form and content. From the Departments of Neurological\J Surgery and Psychiatry, Albert Einstein Col-PSYCHIATRIC STUDIES of patients with lege of Medicine, Bronx, NY. convulsive disorders have shown that Supported by Research Grant NB-06482, e p i s o d i c psychoses resembling schizofrom the National Institute of Neurological i . r .1 Diseases and Blindness, US Public Health P h r e n i a OCCUT , m O S t frequently m paService,tients with the temporal lobe-type or Presented at the One Hundred Twenty-Third epilepsy 3 -27 ' 32 and are not Coincidental,

Cerebrospinal fluid (CSF) drainage catheters can cause a myriad of complications, in large part because they may migrate from their normal location to almost anywhere in the body. We present the unique case of a female patient who had previously undergone bilateral breast augmentation who experienced sudden painless swelling of her right breast 6 weeks after placement of a ventriculoperitoneal shunt. Radiologic examination demonstrated ensnarement of the distal aspect of the shunt around her implant, with subsequent formation of a CSF pseudocyst. Management of this patient included replacement of the shunt, drainage of the CSF pseudocyst, and preservation of the implant.